PDCD1 and neoplasm: Compared with single-target inhibitors, small-molecule compounds that both inhibit PD-L1 expression in tumor cells and disrupt PD-1 activity on CD8+ T cells are more promising to enhance the recognition and killing of tumor cells by CD8+ T cells.